Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Jones Trading

Equities research analysts at Jones Trading began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $45.00 price target on the stock. Jones Trading’s price objective would indicate a potential upside of 61.46% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Canaccord Genuity Group restated a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. TD Cowen assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target for the company. HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Cantor Fitzgerald began coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating on the stock. Finally, Scotiabank assumed coverage on Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $43.20.

Palvella Therapeutics Trading Down 1.0 %

Shares of NASDAQ PVLA opened at $27.87 on Tuesday. The company has a market cap of $312.73 million, a P/E ratio of -2.30 and a beta of 0.54. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $29.27. The business has a 50-day moving average of $19.08.

Institutional Trading of Palvella Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BML Capital Management LLC bought a new position in Palvella Therapeutics in the fourth quarter valued at $506,000. Geode Capital Management LLC purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $171,000. ADAR1 Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $1,736,000. Renaissance Technologies LLC purchased a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $256,000. Finally, Blue Owl Capital Holdings LP bought a new stake in Palvella Therapeutics in the 4th quarter worth approximately $3,001,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.